Wall Street brokerages expect G1 Therapeutics Inc (NASDAQ:GTHX) to announce earnings per share of ($0.98) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for G1 Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.91) and the lowest estimate coming in at ($1.05). G1 Therapeutics posted earnings of ($0.64) per share during the same quarter last year, which suggests a negative year-over-year growth rate of 53.1%. The firm is scheduled to issue its next earnings report on Thursday, May 14th.
On average, analysts expect that G1 Therapeutics will report full-year earnings of ($4.00) per share for the current fiscal year, with EPS estimates ranging from ($4.40) to ($3.55). For the next financial year, analysts anticipate that the business will post earnings of ($4.26) per share, with EPS estimates ranging from ($5.01) to ($3.84). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that follow G1 Therapeutics.
G1 Therapeutics (NASDAQ:GTHX) last announced its earnings results on Wednesday, February 26th. The company reported ($0.94) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.96) by $0.02.
GTHX has been the topic of a number of research reports. BTIG Research raised their target price on shares of G1 Therapeutics from $51.00 to $80.00 and gave the stock a “buy” rating in a research report on Tuesday, January 7th. Wedbush lowered their price objective on shares of G1 Therapeutics from $67.00 to $55.00 and set an “outperform” rating on the stock in a research report on Thursday, February 27th. Cowen reiterated a “buy” rating on shares of G1 Therapeutics in a research report on Thursday, December 12th. HC Wainwright reiterated a “buy” rating and issued a $82.00 price objective (up from $72.00) on shares of G1 Therapeutics in a research report on Tuesday, January 21st. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $74.00 price objective on shares of G1 Therapeutics in a research report on Thursday, December 12th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $59.71.
Shares of GTHX opened at $12.08 on Tuesday. The company has a current ratio of 13.71, a quick ratio of 13.71 and a debt-to-equity ratio of 0.04. The firm has a market cap of $420.46 million, a PE ratio of -3.71 and a beta of 2.11. The company’s 50 day simple moving average is $16.27 and its 200-day simple moving average is $23.18. G1 Therapeutics has a 12-month low of $8.80 and a 12-month high of $41.80.
A number of large investors have recently bought and sold shares of the stock. Franklin Street Advisors Inc. NC acquired a new stake in G1 Therapeutics in the fourth quarter valued at $211,000. Geode Capital Management LLC lifted its holdings in G1 Therapeutics by 3.7% in the fourth quarter. Geode Capital Management LLC now owns 415,705 shares of the company’s stock valued at $10,987,000 after acquiring an additional 14,989 shares during the period. Tang Capital Management LLC lifted its holdings in G1 Therapeutics by 13.3% in the fourth quarter. Tang Capital Management LLC now owns 170,000 shares of the company’s stock valued at $4,493,000 after acquiring an additional 20,000 shares during the period. Cubist Systematic Strategies LLC acquired a new stake in G1 Therapeutics in the fourth quarter valued at $311,000. Finally, UBS Asset Management Americas Inc. lifted its holdings in G1 Therapeutics by 3.2% in the fourth quarter. UBS Asset Management Americas Inc. now owns 252,236 shares of the company’s stock valued at $6,667,000 after acquiring an additional 7,840 shares during the period. Hedge funds and other institutional investors own 80.20% of the company’s stock.
About G1 Therapeutics
G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase Ib/II clinical trials for patients with extensive-stage small cell lung cancer, as well as Phase II clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; lerociclib, an oral CDK4/6 inhibitor that is in Phase Ib/IIa clinical trials for the treatment of breast cancer and in Phase Ib/II clinical trial for non-small cell lung cancer; and G1T48, an oral selective estrogen receptor degrader, which is in Phase I clinical trial.
Further Reading: How are Outstanding Shares Different from Authorized Shares?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.